Mourad Rezk

Senior medical affairs and R&D executive with 30 + years of Biopharmaceutical industry experience and with track record of building and transforming large global medical organizations and leading strategic business development (due diligence, acquisitions and in house developments), with deep experience in strategic planning and developing long term medical and business vision. MD by training with specialty in internal medicine and subspecialty in endocrinology and diabetes management. With broad expertise in immunology, nephrology, hematology, diabetes, and Chronic pain management. With well developed biotech industry career in different senior medical affairs and RnD regional and global roles in world leading Biotech companies (Janssen, NovoNordisk, Biogen and Amgen) Currently working for Biogen as vice president/head of global development and medical affairs for the Biosimilars business Unit (BBU). Substantially contributed to building and leading Biosimilars regional and global medical and development organization (80+ staff members) with highly efficient medical affairs, regulatory , safety , quality and clinical research teams who established Biogen BBU as a scientific partner of choice and helped serving 270,000 patients in 4 different therapeutic areas and more than 20 clinical indications in immunology and ophthalmology while also leading the pipeline expansion with full ownership of developing a pipe line of 3 additional assets with phase I and phase III studies and accountability for regulatory filing.. Highly experienced in clinical development (phase I, II and III) as well as post approval real world evidence data generation and phase IV studies and in setting and executing fit for purpose global medical strategies. Successfully lead Global and EU pre-launches of wide range of novel biological drugs across a large scope of therapeutic areas. Proven business acumen and cross functional collaboration and well established scientific leadership with major contribution to the co-authorship of 50+ publications and speaking in global biotech and medical congresses.

Married and a father of 2

• Canada
• Egypt
• Swiss C permit

• MD
• M.Sc
• MBA

Title: Vice President, Global Head of Medical & Development at Biogen

• Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review., Rezk MF, Pieper B., Adv Ther, 2020 Sep, https://pubmed.ncbi.nlm.nih.gov/32740789/
• The road from development to approval: evaluating the body of evidence to confirm biosimilarity, Paul Declerck, Mourad Farouk Rezk, Rheumatology, Volume 56, Issue suppl_4, 1 August 2017, javascript:;
• An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review., Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R., Ophthalmol Ther, 2022 Jun, https://pubmed.ncbi.nlm.nih.gov/35278204/
• Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect., Rezk MF, Pieper B., Rheumatol Ther, 2017 Dec, https://www.ncbi.nlm.nih.gov/pubmed/29032452
• Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review., Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF., Rheumatol Ther, 2019 Sep, https://pubmed.ncbi.nlm.nih.gov/31385263/
• To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars., Rezk MF, Pieper B., Adv Ther, 2018 Jun, https://pubmed.ncbi.nlm.nih.gov/29873005/
• Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali) Versus Etanercept (Enbrel) - Findings from a Nurse Survey in Europe., Rheumatology and Therapy, Rheumatology and Therapy, June 2016, Volume 3, Issue 1, http://link.springer.com/article/10.1007/s40744-016-0035-1
• Budget Impact Analysis of An Etanercept Biosimilar for The Treatment of All Licensed Etanercept Indications for Adults In Europe., Value Health, Value Health, 2015 Nov, http://www.ncbi.nlm.nih.gov/pubmed/26533586
• Budget Impact Analysis of An Etanercept Biosimilar for The Treatment of Rheumatoid Arthritis In Europe., Value Health, Value Health, 2015 Nov, http://www.ncbi.nlm.nih.gov/pubmed/26533585
• Biosimilarity Versus Manufacturing Change: Two Distinct Concepts., Pharm Res, Pharm Res, 2016 Feb, http://www.ncbi.nlm.nih.gov/pubmed/26381277
• Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study, Nephrol Dial Transplant, Nephrol Dial Transplant, 2016 Apr 15, http://www.ncbi.nlm.nih.gov/pubmed/27190334
• Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study., Pediatr Nephrol, Pediatr Nephrol, 2016 Mar, http://www.ncbi.nlm.nih.gov/pubmed/26482252
• Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study., Adv Ther, Adv Ther, 2014 Nov, http://www.ncbi.nlm.nih.gov/pubmed/24173670
• Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study., Adv Ther, Adv Ther, 2013 Nov, http://www.ncbi.nlm.nih.gov/pubmed/23328710
• Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism., Nephrol Dial Transplant, Nephrol Dial Transplant, 2013 May, http://www.ncbi.nlm.nih.gov/pubmed/21329635
• Epoetin biosimilars in europe: five years on., Adv Ther, Adv Ther, 2013 Jan, http://www.ncbi.nlm.nih.gov/pubmed/21435267
• Extended dosing of darbepoetin alfa in peritoneal dialysis patients., BMC Nephrol, BMC Nephrol, 2011 Mar 24, http://www.ncbi.nlm.nih.gov/pubmed/21435267
• An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months., Clin Nephrol, Clin Nephrol, 2011 Mar, http://www.ncbi.nlm.nih.gov/pubmed/22140136
• Extended dosing of darbepoetin alfa in peritoneal dialysis patients., Feriani BMC Nephrol, BMC Nephrol, 2011 Mar 24, http://www.ncbi.nlm.nih.gov/pubmed/21435267